All Chinese-developed COVID-19 drugs have been included in China’s medical insurance, according to the National Medical Products Administration (NMPA).

(Photo: Xinhua)

This came after two more domestically developed oral medicines were temporarily covered by China’s basic medical insurance after being authorized for treating COVID-19 patients on January 29.

Reimbursement for the two drugs, Xiannuoxin and VV116, will be valid until March 31, as required by the administration in a document aimed at easing financial burdens on residents with relevant needs.

(Compiled by Zhang Tianchen)